NASDAQ:RLYB Rallybio (RLYB) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free RLYB Stock Alerts $1.74 -0.03 (-1.69%) (As of 05:12 PM ET) Add Compare Share Share Today's Range$1.70▼$1.8850-Day Range$1.47▼$2.9852-Week Range$1.23▼$9.14Volume237,569 shsAverage Volume1.35 million shsMarket Capitalization$65.79 millionP/E RatioN/ADividend YieldN/APrice Target$12.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Rallybio alerts: Email Address Rallybio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside601.1% Upside$12.20 Price TargetShort InterestBearish7.60% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.64Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.52) to ($1.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.43 out of 5 starsMedical Sector469th out of 910 stocksPharmaceutical Preparations Industry212th out of 426 stocks 3.4 Analyst's Opinion Consensus RatingRallybio has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageRallybio has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.60% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Rallybio has recently increased by 2.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRallybio does not currently pay a dividend.Dividend GrowthRallybio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLYB. Previous Next 3.7 News and Social Media Coverage News SentimentRallybio has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Rallybio this week, compared to 1 article on an average week.Search Interest7 people have searched for RLYB on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows6 people have added Rallybio to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rallybio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Rallybio is held by insiders.Percentage Held by Institutions90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Rallybio are expected to grow in the coming year, from ($1.52) to ($1.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rallybio is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rallybio is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRallybio has a P/B Ratio of 0.62. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Whats On FinancePutin and other countries have a planDid you catch that bombshell Tucker Carlson interview with Vladimir Putin? It’s not about if you like Tucker or think Putin is the devil or whatever. It's all about the fact that the US dollar might be taking a back seat... and soon. Click to kickstart your journey to survive in the new economy About Rallybio Stock (NASDAQ:RLYB)Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.Read More RLYB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLYB Stock News HeadlinesApril 23, 2024 | finance.yahoo.comFibroGen, Inc. (FGEN)April 22, 2024 | americanbankingnews.comRallybio Co. (NASDAQ:RLYB) Given Average Recommendation of "Moderate Buy" by BrokeragesApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 20, 2024 | americanbankingnews.comRallybio (NASDAQ:RLYB) Rating Reiterated by JMP SecuritiesApril 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT TreatmentApril 17, 2024 | msn.comRallybio (RLYB) Price Target Decreased by 16.00% to 12.85April 17, 2024 | businesswire.comFNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual MeetingApril 15, 2024 | americanbankingnews.comQ1 2024 Earnings Estimate for Rallybio Co. (NASDAQ:RLYB) Issued By WedbushApril 23, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.April 14, 2024 | finance.yahoo.comCozad New Venture Challenge Demo Day awards student start-ups with fundingApril 13, 2024 | americanbankingnews.comRallybio (NASDAQ:RLYB) Price Target Cut to $11.00April 12, 2024 | investing.comRallybio partners with Johnson & Johnson on FNAIT treatmentApril 11, 2024 | msn.comRare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots HigherApril 11, 2024 | proactiveinvestors.comRallybio partners with J&J to advance therapies targeting rare fetal diseaseApril 11, 2024 | msn.comRallybio shares gain on investment from J&J for rare fetal condition treatmentApril 11, 2024 | investorplace.comWhy Is Rallybio (RLYB) Stock Up 93% Today?April 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio on Back of JNJ Collaboration and FNAIT Program ProgressApril 10, 2024 | businesswire.comRallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)April 1, 2024 | finance.yahoo.comRallybio Announces FNAIT Systematic Literature Review to be Presented at the AMCP 2024 Annual MeetingMarch 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio on Strong Drug Pipeline and Market PotentialMarch 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio on Promising FNAIT Treatment and Financial StabilityMarch 12, 2024 | benzinga.comRallybio: Q4 Earnings InsightsMarch 12, 2024 | finance.yahoo.comRallybio Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 26, 2024 | businesswire.comRallybio to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 7, 2024 | msn.comJefferies cuts Rallybio to hold, cites lack of near-term catalystsFebruary 7, 2024 | msn.comRallybio Announces Workforce Reduction and Restructuring CostsFebruary 7, 2024 | markets.businessinsider.comRallybio’s Strategic Focus and Strengthened Fiscal Position Garner Buy RatingSee More Headlines Receive RLYB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/23/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RLYB CUSIPN/A CIK1739410 Webwww.rallybio.com Phone203-59-3820FaxN/AEmployees43Year FoundedN/APrice Target and Rating Average Stock Price Target$12.20 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+601.1%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-56.90% Return on Assets-53.38% Debt Debt-to-Equity RatioN/A Current Ratio12.39 Quick Ratio12.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.62Miscellaneous Outstanding Shares37,810,000Free Float35,014,000Market Cap$65.79 million OptionableNot Optionable Beta-1.64 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesDr. Martin W. MacKay Ph.D. (Age 68)Co-Founder & Executive Chairman Comp: $723.35kDr. Stephen Uden M.B (Age 66)M.D., Co-Founder, President, CEO & Director Comp: $723.35kMr. Jonathan I. Lieber M.B.A. (Age 54)CFO & Treasurer Comp: $667.13kKey CompetitorsImmix BiopharmaNASDAQ:IMMXCelularityNASDAQ:CELULandos BiopharmaNASDAQ:LABPMarinus PharmaceuticalsNASDAQ:MRNSKronos BioNASDAQ:KRONView All CompetitorsInstitutional Ownershipabrdn plcBought 1,727,067 shares on 1/31/2024Ownership: 4.570%View All Institutional Transactions RLYB Stock Analysis - Frequently Asked Questions Should I buy or sell Rallybio stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rallybio in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RLYB shares. View RLYB analyst ratings or view top-rated stocks. What is Rallybio's stock price target for 2024? 6 Wall Street analysts have issued 12-month target prices for Rallybio's shares. Their RLYB share price targets range from $8.00 to $18.00. On average, they predict the company's share price to reach $12.20 in the next year. This suggests a possible upside of 601.1% from the stock's current price. View analysts price targets for RLYB or view top-rated stocks among Wall Street analysts. How have RLYB shares performed in 2024? Rallybio's stock was trading at $2.39 at the start of the year. Since then, RLYB stock has decreased by 27.2% and is now trading at $1.74. View the best growth stocks for 2024 here. When is Rallybio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RLYB earnings forecast. How were Rallybio's earnings last quarter? Rallybio Co. (NASDAQ:RLYB) announced its quarterly earnings data on Tuesday, March, 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by $0.06. When did Rallybio IPO? Rallybio (RLYB) raised $80 million in an initial public offering on Thursday, July 29th 2021. The company issued 5,750,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of Rallybio? Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RLYB) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHow to camouflage a factory of 53,000 workersStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsGoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
